StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Creon (pancrelipase) — U.S. reported growth YoY by Quarter

Creon (pancrelipase) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Creon (pancrelipase) — U.S. reported growth YoY: -14.7% in Q2 2026, down 23.1 pts from a year earlier. That is the lowest of the 35 quarters on record here.

Latest, Q2 2026
-14.7%
Period ended Jun 30, 2026
Change on a year earlier
-23.1 pts
8.4% in Q2 2025
History
35 quarters
Since Q4 2017
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Creon | 345 | — | 345 | (14.7) | n/m | (14.7) | n/m | (14.7)”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCreon (pancrelipase) — U.S. reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-14.7%-23.1 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 20261.8%-22.8 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025-0.8%-4.1 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20259.1%-1.5 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20258.4%-23.7 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202524.6%+31.2 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 20243.3%-8.2 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202410.6%+19.7 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202432.1%+43.5 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-6.6%-12.9 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202311.5%+8.5 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-9.1%-17.6 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-11.4%-25.0 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20236.3%+1.6 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20223.0%-4.8 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 20228.5%-1.5 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Creon (pancrelipase) — U.S. reported growth YoY (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/creon-us-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.